Huang X, Cai SL, Xie LP. Prostatic carcinosarcoma seven years after radical prostatectomy and hormonal therapy for prostatic adenocarcinoma: A case report. World J Clin Cases 2021; 9(22): 6388-6392 [PMID: 34435003 DOI: 10.12998/wjcc.v9.i22.6388]
Corresponding Author of This Article
Xiao Huang, MD, PhD, Chief Doctor, Professor, Surgeon, Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310030, Zhejiang Province, China. xiaohuang69@zju.edu.cn
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2021; 9(22): 6388-6392 Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6388
Prostatic carcinosarcoma seven years after radical prostatectomy and hormonal therapy for prostatic adenocarcinoma: A case report
Xiao Huang, Song-Liang Cai, Li-Ping Xie
Xiao Huang, Song-Liang Cai, Li-Ping Xie, Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310030, Zhejiang Province, China
Author contributions: Huang X analyzed the data and wrote the manuscript; Cai SL performed the surgery and collected the data; Xie LP contributed to manuscript reviewing; all authors have read and approved the final manuscript.
Supported bythe Natural Science Foundation of Zhejiang Province, China, No. LY19H050008.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao Huang, MD, PhD, Chief Doctor, Professor, Surgeon, Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310030, Zhejiang Province, China. xiaohuang69@zju.edu.cn
Received: January 10, 2021 Peer-review started: January 10, 2021 First decision: February 11, 2021 Revised: February 28, 2021 Accepted: June 16, 2021 Article in press: June 16, 2021 Published online: August 6, 2021 Processing time: 198 Days and 10.4 Hours
Abstract
BACKGROUND
Prostatic carcinosarcoma is a very rare and highly aggressive tumor. It may occur after androgen deprivation therapy (ADT) for adenocarcinoma even after a 7-year interval.
CASE SUMMARY
A 66-year-old man presented with recurrent symptoms of gross hematuria and urinary retention. The patient had a previous history of combined radical prostatectomy and ADT for prostate cancer 7 years prior. He received total pelvic exenteration for a recurrent pelvic carcinosarcoma. Pathology and immunostaining revealed a carcinosarcoma of prostatic origin with focal spindled cells and bizarre giant cells. The patient subsequently underwent transverse colostomy for carcinosarcoma recurrence and bowel obstruction 3 mo later. Five months after the diagnosis of prostatic carcinosarcoma, the patient died of multiple organ metastases.
CONCLUSION
Prostatic carcinosarcoma after adenocarcinoma is exceedingly rare. ADT mediated transformation and dedifferentiation of the epithelial components may be the origin of this malignancy.
Core Tip: This is an unusual case of delayed occurrence of prostatic carcinosarcoma 7 years after radical prostatectomy and androgen deprivation therapy (ADT) for prostatic adenocarcinoma. It is very uncommon for a patient to have both neoplasms. ADT mediated transformation and dedifferentiation of the epithelial component may be the origin of this malignancy.
